In Memorium - Dr. Jim Roth
It is with great sadness that we share with you that Dr. Jim Roth,
Chair/Chief, Division of Orthopaedic Surgery, Department of Surgery,
Schulich Medicine & Dentistry has passed away.
Dr. Roth was a beloved and renowned physician and a very proud Western alumnus. Read More...
Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21)
Submission Dates: July 2, 2012; Nov 1, 2012, March 1, 2013, July 1, 2013
encourages exploratory/developmental clinical research related to the prevention or treatment of arthritis and musculoskeletal and skin diseases, conditions, and/or injuries. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to gather critical preliminary data in support of a future, planned clinical trial. They can include testing new or prevention strategies, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice.
Direct costs are limited to $275,000 over an R21 two-year period
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)
Submission Dates: July 11, 2012; November 13, 2012; March 13, 2013; July 11, 2013; November 13, 2013; March 13, 2014, by 5:00 PM local time of applicant organization.
intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.
All awards are for up to $500,000 in Direct Costs over 2 years.